GlassScriptPhysician profile
Justin T Ray
NPI 1093013641
$127,413.30
in general payments reported to CMS, 2019-2025
27 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,468 · 2022: $4,479 · 2023: $27K · 2024: $28K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Honoraria: $17K · Food and Beverage: $7,963 · Travel and Lodging: $7,893 · Education: $19.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,365.00 |
| Honoraria | $17,226.00 |
| Food and Beverage | $7,963.03 |
| Travel and Lodging | $7,892.51 |
| Education | $19.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $57,907.45 | 2021-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $40,407.33 | 2021-2025 | |
| Axsome Therapeutics, INC. | $22,805.13 | 2022-2025 | Auvelity |
| Allergan, INC. | $1,100.00 | 2021 | |
| Alkermes, INC. | $876.88 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $867.32 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $510.22 | 2021-2022 | |
| Lundbeck LLC | $432.17 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $341.33 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $338.31 | 2021-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $313.04 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $250.17 | 2022-2025 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $217.79 | 2021-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $169.63 | 2021-2025 | Qelbree |
| Averitas Pharma INC. | $150.47 | 2025 | Qutenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $135.87 | 2021-2023 | Adzenys Xr-Odt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $110.88 | 2023 | |
| Ironshore Pharmaceuticals INC. | $104.33 | 2024 | |
| Almatica Pharma LLC | $95.71 | 2022-2024 | Loreev Xr |
| Corium, LLC | $80.81 | 2022-2024 | Azstarys |
| Tris Pharma INC | $55.55 | 2022-2024 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $55.44 | 2021-2022 | |
| Indivior INC. | $25.88 | 2025 | Sublocade |
| Collegium Pharmaceutical, INC. | $20.72 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $14.93 | 2024 | Quviviq |
| Bausch Health US, LLC | $14.50 | 2022 | |
| Adlon Therapeutics L.P. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.